SinoMab BioScience Limited

SEHK:3681 Stock Report

Market Cap: HK$1.2b

SinoMab BioScience Management

Management criteria checks 3/4

SinoMab BioScience's CEO is Shawn Leung, appointed in Jan 2001, has a tenure of 23.92 years. total yearly compensation is CN¥5.11M, comprised of 99.7% salary and 0.3% bonuses, including company stock and options. directly owns 11.88% of the company’s shares, worth HK$142.70M. The average tenure of the management team and the board of directors is 3.1 years and 5 years respectively.

Key information

Shawn Leung

Chief executive officer

CN¥5.1m

Total compensation

CEO salary percentage99.7%
CEO tenure23.9yrs
CEO ownership11.9%
Management average tenure3.1yrs
Board average tenure5yrs

Recent management updates

Recent updates

Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

Mar 04
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year

What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Jan 28
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition

Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Jan 01
Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?

Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

Nov 30
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term

CEO Compensation Analysis

How has Shawn Leung's remuneration changed compared to SinoMab BioScience's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥200m

Mar 31 2024n/an/a

-CN¥221m

Dec 31 2023CN¥5mCN¥5m

-CN¥243m

Sep 30 2023n/an/a

-CN¥259m

Jun 30 2023n/an/a

-CN¥274m

Mar 31 2023n/an/a

-CN¥279m

Dec 31 2022CN¥5mCN¥5m

-CN¥284m

Sep 30 2022n/an/a

-CN¥301m

Jun 30 2022n/an/a

-CN¥318m

Mar 31 2022n/an/a

-CN¥303m

Dec 31 2021CN¥4mCN¥4m

-CN¥288m

Sep 30 2021n/an/a

-CN¥222m

Jun 30 2021n/an/a

-CN¥156m

Mar 31 2021n/an/a

-CN¥139m

Dec 31 2020CN¥5mCN¥4m

-CN¥123m

Compensation vs Market: Shawn's total compensation ($USD699.59K) is above average for companies of similar size in the Hong Kong market ($USD352.07K).

Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.

CEO

Shawn Leung (64 yo)

23.9yrs

Tenure

CN¥5,106,000

Compensation

Dr. Shui On Leung, also known as Shawn, serves as Chief Executive Officer of SinoMab BioScience Limited since January 2003 and also serves as its Director and Chairman of the Board since April 27 2001 and...

Leadership Team

NamePositionTenureCompensationOwnership
Shui On Leung
Founder23.9yrsCN¥5.11m11.88%
HK$ 142.7m
Jianping Hua
Chief Financial Officer5.9yrsno datano data
Yuande Zhang
Director of Marketing1.8yrsno datano data
Lixin Zhang Auberson
Chief Medical Officer3.3yrsno datano data
Shanchun Wang
President of China & Executive Director2.9yrsno data1.19%
HK$ 14.2m
Yuk Yin Chow
Company secretary1.8yrsno datano data

3.1yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 3681's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Shui On Leung
Founder23.7yrsCN¥5.11m11.88%
HK$ 142.7m
Shanchun Wang
President of China & Executive Directorless than a yearno data1.19%
HK$ 14.2m
Ping Cho Hon
Independent Non-Executive Director5.2yrsCN¥283.00kno data
Haigang Chen
Non-Executive Director7.3yrsno datano data
Dylan Carlo Tinker
Independent Non-Executive Director5.2yrsCN¥283.00kno data
Xun Dong
Non-Executive Director5yrsno datano data
George William Hunter Cautherley
Independent Non Executive Director5yrsCN¥283.00kno data
Chi Ming Lee
Independent Non-Executive Director3.5yrsCN¥283.00kno data
Jianmin Zhang
Non-Executive Director1.3yrsno datano data
Xiaosu WANG
Non-Executive Directorno datano datano data

5.0yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 3681's board of directors are considered experienced (5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 12:21
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SinoMab BioScience Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue-Kwong LuiJefferies LLC